Can a Psychiatric-Mental-Health Nurse Practitioner prescribe glucagon-like peptide-1 (GLP-1) receptor agonists for treating addiction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can PMHNPs Prescribe GLP-1 for Addiction?

Whether a PMHNP can prescribe GLP-1 receptor agonists for addiction depends entirely on state-specific scope of practice laws and prescriptive authority, not on the clinical evidence for these medications in treating substance use disorders. The clinical question of whether GLP-1 RAs work for addiction is separate from the regulatory question of who can prescribe them.

Scope of Practice Considerations

The ability of PMHNPs to prescribe GLP-1 receptor agonists hinges on:

  • State prescriptive authority: Most states grant PMHNPs full or collaborative prescriptive authority for medications within their scope of practice
  • Off-label prescribing rights: GLP-1 RAs are FDA-approved only for diabetes and obesity, not addiction—off-label prescribing authority varies by state
  • Practice setting policies: Hospital systems, clinics, and insurance panels may impose additional restrictions beyond state law
  • Collaborative practice agreements: Some states require physician oversight for certain medication classes or off-label use

The critical caveat: Even where legally permitted, prescribing GLP-1 RAs for addiction currently represents off-label use without FDA approval for this indication, which carries medicolegal considerations around informed consent and documentation.

Clinical Evidence for GLP-1 RAs in Addiction

While not directly addressing prescriber qualifications, the evidence base is relevant to clinical decision-making:

Preclinical and Emerging Clinical Support

Robust preclinical evidence demonstrates that GLP-1 receptor agonists reduce substance intake and seeking behaviors across alcohol, nicotine, opioids, and psychostimulants through modulation of mesolimbic dopamine signaling and reward circuitry 1, 2, 3, 4.

Early clinical trials show promise particularly for alcohol use disorder, with reductions in consumption and craving, though sample sizes remain small and follow-up periods short 1, 3, 4. Clinical trials are ongoing for multiple substance use disorders, with 33 registered trials as of 2025—predominantly focused on alcohol (n=15) and nicotine/tobacco (n=9), with notable gaps for methamphetamine and cannabis use disorders 5.

Mental Health Safety Profile

GLP-1 RAs do not increase psychiatric adverse events or worsen depression compared to placebo, and may actually improve quality of life, emotional eating, and restrained eating behaviors 6. This addresses early pharmacovigilance concerns and is particularly relevant for PMHNP practice with patients who have co-occurring psychiatric conditions.

Mechanism and Rationale

GLP-1 receptors in the nucleus accumbens, ventral tegmental area, hypothalamus, and brainstem nuclei mediate both metabolic regulation and reward-driven behaviors 3, 4, 7. This dual action makes GLP-1 RAs particularly suitable for patients with co-occurring obesity and substance use disorders—a common clinical scenario given shared pathophysiology involving dysregulated reward circuitry 4, 7.

Practical Clinical Algorithm

If legally permitted in your jurisdiction:

  1. Assess suitability: Prioritize patients with co-occurring obesity (BMI ≥30 or ≥27 with comorbidities) or type 2 diabetes, where GLP-1 RAs have established FDA-approved indications that overlap with emerging addiction benefits

  2. Target substance: Strongest evidence exists for alcohol use disorder, followed by nicotine/tobacco; limited data for opioids, cocaine, and methamphetamine; essentially no data for cannabis 5, 3

  3. Informed consent: Document thoroughly that this represents off-label use for addiction, explain the preliminary nature of evidence, and discuss FDA-approved alternatives for substance use disorders

  4. Monitor cardiometabolic benefits: Track weight, blood pressure, lipid profiles, and inflammatory markers—these patients often have elevated cardiovascular risk that GLP-1 RAs may address simultaneously 7

  5. Coordinate care: Given the novelty of this approach and potential need for endocrinology consultation (especially if diabetes is present), establish clear communication with other providers

Critical Gaps and Cautions

The evidence base remains preliminary 1, 5, 3. Randomized controlled trials are critically needed to establish optimal dosing, duration, predictors of response, and long-term safety specifically in addiction populations. Current clinical use represents emerging practice rather than established standard of care.

Physician reluctance to intervene in addiction is well-documented across specialties 8, but this should not deter appropriately credentialed PMHNPs from considering evidence-based interventions within their scope of practice, particularly given the magnitude of the addiction crisis and limited existing pharmacological options 8.

Peri-operative considerations are important if patients require surgery: GLP-1 RAs cause delayed gastric emptying and increased aspiration risk, requiring medication holds of at least three half-lives (up to 3 weeks for semaglutide) before procedures 9.

References

Related Questions

Which antidepressants are appropriate for a patient with type 2 diabetes on a GLP‑1 receptor agonist, considering weight effects and drug interactions?
Can a person with alcohol use disorder be prescribed a GLP‑1 receptor agonist?
Can glucagon-like peptide‑1 (GLP‑1) receptor agonists be used for opioid use disorder?
Does glucagon-like peptide-1 (GLP-1) affect serotonin levels?
Do glucagon-like peptide-1 receptor agonists reduce alcohol cravings?
If I lower the insulin-to-carbohydrate ratio on my insulin pump and increase the insulin sensitivity factor, will these changes balance each other out?
What is the appropriate workup for inflammatory arthritis in a 34‑year‑old patient?
For a patient with a cellular biologic graft who had negative‑pressure wound therapy (VAC) discontinued due to heavy drainage requiring frequent outer dressing changes, should I restart NPWT over the graft using a petroleum‑impregnated (Vaseline) gauze or other non‑adherent interface to protect the biologic, and what are the recommended NPWT pressure settings and dressing change intervals?
Does a negative β‑D‑glucan test exclude infection with dimorphic fungi?
Is olanzapine appropriate for patients with established cardiac disease, and what dosing and monitoring precautions are recommended?
What is the most appropriate antibiotic for a urinary infection caused by Citrobacter koseri in an adult with normal renal function and no drug allergies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.